Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416251 | 0.80 | — | — | |
| SCHEMBL2570605 | 0.79 | CDK2 (0.35) | — | |
| SCHEMBL1763395 | 0.79 | CDK2 (0.35) | — | |
| SCHEMBL458641 | 0.76 | — | — | |
| SCHEMBL31015214 | 0.76 | DNM2 (0.31) | — | |
| SCHEMBL906610 | 0.75 | KCNH2 (0.43) | — | |
| SCHEMBL15401167 | 0.75 | — | — | |
| SCHEMBL2418880 | 0.75 | MAPT (0.32) | — | |
| SCHEMBL31014356 | 0.72 | PDE10A (0.36) | — | |
| SCHEMBL12615302 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362872-A2 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011088160-A2 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010062506-A2 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | LEAD THERAPEUTICS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100105700-A1 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | HRH3 4745/4885 |
| US-20100105700-A1 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | CYP17A1, HSD17B1, CYP21A2 | HRH3 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.